Systemic sclerosis (SSc) is associated with interstitial lung diseases. The primary endpoints of this study were changes between baseline and month 24 in single-breath carbon monoxide diffusing capacity (DLco). The secondary endpoints were: vital capacity (VC), forced expired volume in 1 sec (FEVl), total lung capacity (TLC), scores of high resolution computed tomography (HRCT) of the chest, number of adverse effects. In this study, we retrospectively investigated data from SSc patients who had undergone therapy with high-dose intravenous N-acetylcysteine (NAC) at a dosage of 15 mg/Kg/h for 5 consecutive hours every 14 days. After NAC therapy median values ofDLco (69.5% vs 77.7%), VC (99% vs 101.3%) and TLC (93% vs 98.3%) significantly increased. We did not observed any significant changes from baseline in FEVI value and HRTC score. The improvement in lung function was more evident in SSc patients without radiological signs of pulmonary fibrosis than in patients with pulmonary fibrosis. In SSc patients with mild-moderate pulmonary fibrosis intravenous NAC administration slows the rate of deterioration ofDLco, VC and TLC. In conclusion, this retrospective study demonstrates that long-term therapy with intravenous NAC ameliorates pulmonary function tests in SSc patients.
Systemic sclerosis (SSc) is a chronic connective tissue disease characterized by endothelial dysfunction and fibrosis of the skin and internal organs. Microangiopathy is one of the main histopathologic features that is detectable early in the course of the disease (1). Pulmonary fibrosis is the end stage of many chronic lung diseases including SSc and idiopathic pulmonary fibrosis (lPF) (2) . The molecular mechanisms underlying the pathogenesis and progression of lung fibrosis in these diseases are not entirely clear. An oxidant-antioxidant imbalance may contribute to the disease process in SSc and IPF (3) (4) .
Acetylcysteine, a precursor of the major antioxidant glutathione, given at a daily dose of 1800 mg, has been shown to improve lung function in patients with IPF, but a lower dosage did not ameliorate pulmonary function of SSc patients (5) (6) (7) .
For its properties of the enhancement of the glutathione system, elimination of peroxides, and maintenance of ascorbate and a-tocopherol in their reduced states, N-acetylcysteine (NAC) is used in improving myocardial function following an acute myocardial infarction, protecting the kidneys from damage by hypertension, improving endothelial dysfunction in dialysis patients, and reducing radiocontrast-induced nephropathy. In SSc patients NAC plus standard therapy is also used in the treatment of Raynaud's phenomenon and digital ulcers (8) .
In a retrospective study our aim is to assess the long-term effects of high dose intravenous NAC on pulmonary function in SSc patients undergoing NAC infusion plus oral nifedipine for Raynaud's phenomenon and digital ulcer treatment
MATERIALS AND METHODS

Study design
This retrospective study was carried out in the Clinical Immunology Unit-Scleroderma Center of Sapienza University of Rome to evaluate the effects of NAC infusion in pulmonary function of SSc patients. All consecutive patients with SSc who fulfilled inclusion criteria were enrolled in the study. After approval by the Institutional Review Board and patient informed consent, the patients who met the American College of Rheumatology (ACR) criteria (9) for SSc and were treated with NAC were retrospectively identified.
Inclusion criteria
The patients included in the study had been diagnosed as having SSc and had received NAC infusion, associated to oral nifedipine, for the treatment of Raynaud's phenomenon and digital ulcers according to our previous study (8) . A duration of NAC therapy longer than 24 months was required for study inclusion. All patients had annual or biannual measurements of pulmonary function tests (PFT).
Clinical characteristics, pulmonary function data, and chest high resolution computed tomography (HRCT) results were obtained by chart review. We collected PFTs measurements made up to 6 months prior to starting NAC and at the last available follow-up (24 months) of NAC. Measurements made closest to the time NAC was started were designated as those at "baseline". PFTs at baseline were compared with PFTs 12 and 24 months after treatment onset. The media of two PFT measurements was calculated.
HRCTs were evaluated at baseline and after NAC therapy (at least 20 months after NAC start). The HRCT was judged to have improved, remained unchanged, or worsened in the pre-NAC and NAC treatment intervals according to HRTC score. The baseline PFTs and HRTC abnormalities did not affect the selection of the patients.
Exclusion criteria
None of the patients had received treatment with oral and parenteral NAC, prostanoids or bosentan for at least 12 months prior to this study-point. Patients in therapy with prostacyclin analogues, phosphodiesterase 5 inhibitors, endothelin receptor antagonists, prednisone, azathioprine, cyclophosphamide, methotrexate and TNFablocking agents, overlap syndrome, idiopathic pulmonary fibrosis, other causes of interstitial lung diseases (lLD) other than from SSc, pulmonary arterial hypertension, asthma, chronic obstructive pulmonary disease (COPD), rhinosinusitis, systemic hypertension, cardiac failure, hepatic failure, diabetics, coagulopathy, smokers, pregnant or breastfeeding women were excluded.
Study population
Forty-one patients [37 female and 4 male; median age 47.5 years (range 23-70)], median duration ofRP 10 years (range 6-38]) and median duration ofSSc 7.5 years (range 1-37) fulfilling ACR criteria for the classification of SSc were enrolled in this study (9) . SSc patients had undergone NAC therapy from January, 2008 to December, 20 IO. All patients who fulfilled the ACR criteria for SSc were subsequently divided into a limited (IcSSc) and a diffuse (dcSSc) cutaneous SSc group according to LeRoy (10) . Eighteen patients had limited cutaneous SSc (IcSSc) and 23 had diffuse cutaneous SSc (dcSSc). Eighteen patients had history of digital ulcers. Eleven patients were anti-centromere antibody positive and 16 were antitopoisomerase antibody positive (Table I) .
Pulmonary function tests
Single-breath CO-diffusing capacity (DLco) corrected for hemoglobin concentration, vital capacity (YC), forced expired volume in 1 sec (FEY I) and total lung capacity (TLC), expressed as percentages of the predicted normal values, were measured according to the European Respiratory Society (ERS) guidelines ( 11-12).
Radiologic assessment
High resolution computed tomography (HRCT) of the chest was performed at baseline and after 24 months of NAC therapy. HRCT was classified according to score of ground-glass opacities and of fibrosis on high-resolution CT [ranging from 0 (minimum) to 5 (maximum)] (\3).
Outcomes
The primary end point is the changes in Dl.co, as percentages of the predicted value, between baseline and month 24. The following secondary end points were assessed for changes between baseline and 24 months: YC, FEY I, TLC, scores of HRCT, number of adverse effects.
Medical treatment
NAC was administered in the form of 5 consecutive hours intravenous infusion at a dosage of 15mg/Kg/h every 14 days. All patients were treated for 24 months with NAC infusion. SSc patients underwent therapeutic treatment with calcium channel blockers (nifedipine 30 mg/day) and proton pump inhibitors for gastroesophageal reflux disease.
Statistical analysis
Continuous data are presented as medians with ranges or 95% confidence intervals (CIs); P values < 0.05 were considered statistically significant. Commercially available software (SPSS version 18.0; SPSS, Inc, Chicago, Illinois) was used for the statistical analysis. Non-parametric tests (chi-square test and Fisher exact test) were used for categorical variables. All data were examined to see whether assumptions of normality held true. The coefficient of skewness and coefficient of kurtosis were used to evaluate normal distribution of data. The assumptions of normality cannot be assumed within the data set particularly due to the small sample size, therefore non-parametric tests were used throughout. The Mann-Whitney U-test was used to test differences between two individual study groups. Wilcoxon signed rank test was used to compare results at different time points.
RESULTS
After 24 months of NAC therapy, median values ofOLco (69.5% vs 77.7%), YC (99% vs 101.3%) and TLC (93% vs 98.3%) significantly increased (Table  II) . We did not observe any significant changes from baseline in FEYI value. Seventeen patients showed radiological signs of pulmonary fibrosis ranging from I to 2 of HRCT score. After NAC therapy the HRCT score did not show significant changes from baseline (Table II) .
In SSc patients without HRCT, signs of pulmonary fibrosis median value of OLco were significantly (p<O.OOO I) higher than in SSc patients with pulmonary fibrosis (72% vs 65%). After NAC therapy the OLco increase is higher (p<O.OO I) in patients without HRCT signs of pulmonary fibrosis than in patients with fibrosis (83% vs 70%) (Fig. I) .
The median value of Dl.co Delta between baseline and post therapy was significantly (p<O.OO I) higher in SSe patients without HRCT pulmonary fibrosis than in SSc patients with pulmonary fibrosis [9 (-2+29) vs I -(8+21)] (Fig. I) . In patients without HRCT pulmonary fibrosis YC increased significantly (p= 0.02) after therapy [100% (70-121) vs 102% (72-129)]. In SSc patients with HRCT pulmonary signs of fibrosis YC increased not significantly after therapy [94.5% (68-115) vs 95% (56-116)] (Fig. 2) .
In patients without HRCT pulmonary fibrosis TLC increased significantly (p= 0.008) after therapy [96.5% (61-117) vs 100.5% (76-123)]. In SSe patients with HRCT pulmonary signs of fibrosis TLC increased not significantly (p>0.05) after therapy[92% (68-115] vs 94% (83-107)] (Fig. 2) . No significant changes of FEYI in patients with or without HRCT pulmonary signs of fibrosis were observed.
No severe reactions to infusion were recorded .. and NAC infusion was generally well tolerated. Two patients (5%) reported minor side effects (flushing and headache). None of the patients had to discontinue the treatment.
DISCUSSION
Our results show that long-term intravenous NAC in SSc patients significantly improves Dl.co, VC and TLC. The improvement in lung function is most evident in SSc patients without radiological signs of pulmonary fibrosis than in patients with pulmonary fibrosis. In SSc patients with mild-moderate pulmonary fibrosis intravenous NAC administration slows the rate of deterioration of PFTs (OLco, VC and TLC).
Previous studies demonstrate that NAC infusion improves Raynaud's phenomenon (RP) and prevents the formation of digital ulcers (8, 14) . In addition, intravenous NAC therapy ameliorates renal and hepatic function in early stage of SSc patients without adverse effects (15) (16) . In addition to mucolytic effects in COPO and anti-fibrotic effect in IPF, the NAC is also an effective vasodilator in the treatment of RP secondary to SSc (17) . This vasodilator effect is more evident in the early stage of the disease compared to the late stage, which is characterized by disorganization of the capillary architecture (15) (16) .
The pathogenetic mechanism of lung fibrosis in SSc is not clear. HSU et al. demonstrated distinct molecular profiles in tissues and fibroblasts from patients with SSc-associated lung disease compared to idiopathic forms oflung disease. The most common histological pattern ofSSc-associated interstitial lung disease (lLD) is non-specific interstitial pneumonia (NSIP), instead the characteristic pattern of IPF is usual interstitial pneumonia (VIP). No treatment regimen has been shown to improve survival in IPF. Conversely, in SSc-ILD the immunosuppressive treatment shows beneficial effects mainly for patients with active alveolitis. The pathogenetic mechanism in IPF is an aberrant and irreversible fibrosis. In SSc the reactive oxygen species (ROS) production and microvascular damage seem to play a key role on SSc-ILD (18) . Unstimulated skin fibroblasts from SSc patients released more ROS in vitro through the NADPH oxidase complex pathway than normal fibroblasts. The constitutive intracellular production of ROS by SSc fibroblasts derives from the activation of an NADPH oxidase-like system and it is essential to fibroblast proliferation and expression of type I collagen genes in SSc cells (19) . Pulmonary fibrosis develops in connective tissue diseases with pathogenetically established immunebased microvascular injury. A similar mechanism of antibody-mediated endothelial cell injury may be the basis of the tissue injury and fibrosing reparative response (20) .
NAC therapy shows contradictory effects in ILD. Different studies demonstrate that NAC, administered in three 600-mg effervescent tablets, had concomitant favorable effects on lung function ofIPF patients (5) (6) . By contrast, in a single previous study NAC therapy, administered in 500 mg capsules, did not produce significant changes on lung function of SSc patients. (7) . In respect to previous studies, we administered intravenous NAC high dose with positive results on lung function of SSc patients. The positive results of NAC in lung function could be attributed by a reduction of NADPH oxidase complex activation with fibroblast proliferation and ROS-induced microvascular damage. Positive NAC effects on the lung microvasculature are demonstrated in animal models. NAC attenuates lung damage, pulmonary emphysema and alveolar septal cell apoptosis by partly reversing the decrease in VEGF secretion and VEGFR2 protein expression in smoking-induced chronic obstructive pulmonary disease in rats (21) .
The NAC infusion proves its effectiveness especially in the early stages of lung disease where the damage is not irreversible for the pulmonary fibrosis absence. In our opinion, the effects of NAC on the primary and secondary endpoints have a double clinical relevance: in patients without radiological signs of fibrosis NAC infusion ameliorates pulmonary function without adverse effects; in patients with pulmonary radiological fibrosis, NAC slows the rate of deterioration of the primary and secondary pulmonary end points without side effects.
In conclusion, the present study, albeit with the limitations of a retrospective single study, demonstrates that long-term therapy with NAC in SSc patients ameliorates pulmonary function. Prospective double-blind randomized studies are needed to confirm these preliminary data.
